Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
9.01
-0.30 (-3.22%)
At close: Jul 31, 2026, 4:00 PM EDT
9.17
+0.16 (1.78%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Kura Oncology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 39.08 | 149.1 | 224.46 | 37.32 | 51.8 | 90.67 |
Short-Term Investments | 541.74 | 518.14 | 502.93 | 386.64 | 386.18 | 427.29 |
Cash & Short-Term Investments | 580.82 | 667.24 | 727.4 | 423.96 | 437.99 | 517.96 |
Cash Growth | -11.76% | -8.27% | 71.57% | -3.20% | -15.44% | -18.21% |
Accounts Receivable | 9.35 | 8.8 | 2.06 | - | - | - |
Inventory | 0.84 | 0.41 | - | - | - | - |
Other Current Assets | 32.77 | 32.21 | 15.37 | 8.52 | 8.44 | 4.33 |
Total Current Assets | 623.78 | 708.66 | 744.83 | 432.48 | 446.43 | 522.29 |
Net Property, Plant & Equipment | 14.78 | 15.16 | 7.49 | 8.68 | 6.38 | 8.25 |
Other Long-Term Assets | 13.99 | 14.54 | 7.85 | 7.6 | 3.5 | 3.52 |
Total Assets | 652.55 | 738.36 | 760.16 | 448.94 | 456.31 | 534.05 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 7.04 | 5.02 | 1.47 | 33.76 | 21.74 | 20.19 |
Accrued Expenses | 45.47 | 61.7 | 48.48 | - | - | - |
Current Portion of Long-Term Debt | - | - | 2.61 | - | - | - |
Current Portion of Leases | 1.28 | 1.28 | 1.88 | 1.51 | 2.32 | 2.26 |
Unearned Revenue | 47.7 | 48.98 | 24.27 | - | - | - |
Total Current Liabilities | 101.5 | 116.97 | 78.71 | 35.26 | 24.06 | 22.46 |
Long-Term Debt | 9.75 | 9.71 | 6.92 | 9.33 | 9.16 | - |
Long-Term Leases | 13.24 | 9.47 | 5.19 | 6.36 | 2.55 | 4.61 |
Other Long-Term Liabilities | 420.18 | 428.07 | 255.7 | 0.71 | 0.27 | 0.38 |
Total Long-Term Liabilities | 443.17 | 447.25 | 267.81 | 16.4 | 11.97 | 4.99 |
Total Liabilities | 544.67 | 564.23 | 346.52 | 51.66 | 36.03 | 27.44 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,356 | 1,347 | 1,308 | 1,120 | 997.11 | 941.36 |
Accumulated Other Comprehensive Income | -0.38 | 1.02 | 0.76 | -1.27 | -8.03 | -1.79 |
Retained Earnings | -1,247 | -1,174 | -895.42 | -721.44 | -568.81 | -432.97 |
Shareholders' Equity | 107.88 | 174.14 | 413.64 | 397.27 | 420.28 | 506.61 |
Total Liabilities & Equity | 652.55 | 738.36 | 760.16 | 448.94 | 456.31 | 534.05 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 24.27 | 20.46 | 16.59 | 17.2 | 14.02 | 6.88 |
Net Cash (Debt) | 556.55 | 646.78 | 710.8 | 406.76 | 423.96 | 511.09 |
Net Cash Growth | -12.88% | -9.01% | 74.75% | -4.06% | -17.05% | -17.62% |
Net Cash Per Share | 6.33 | 7.38 | 8.25 | 5.55 | 6.33 | 7.70 |
Book Value | 107.88 | 174.14 | 413.64 | 397.27 | 420.28 | 506.61 |
Book Value Per Share | 1.23 | 1.99 | 4.80 | 5.43 | 6.27 | 7.64 |
Tangible Book Value | 107.88 | 174.14 | 413.64 | 397.27 | 420.28 | 506.61 |
Tangible Book Value Per Share | 1.23 | 1.99 | 4.80 | 5.43 | 6.27 | 7.64 |